We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GBR 1342 is designed to activate the patient’s immune system by redirecting immune cells towards tumour tissue, which may lead to targeted destruction of tumours